Common (1% to 10%): Oropharyngeal pain
Very common (10% or more): Elevated baseline creatine phosphokinase (CPK) (14%)
Uncommon (0.1% to 1%): Anaphylaxis
Common (1% to 10%): Treatment emergent anti-reslizumab (the active ingredient contained in Cinqair) antibody response (low titer and often transient)
Very common (10% or more): Elevated baseline creatine phosphokinase (CPK) (14%)Common (1% to 10%): Myalgia, chest pain, neck pain, muscle spasms, extremity pain, muscle fatigue, musculoskeletal pain
Frequency not reported: Malignancy
Cough
difficulty with swallowing
dizziness
dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
fast heartbeat
hives, itching, or skin rash
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
redness of the skin
tightness in the chest
unusual tiredness or weakness
Throat pain
Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site